D. Boral Capital Reaffirms Buy Rating for Invivyd (NASDAQ:IVVD)

Invivyd (NASDAQ:IVVD)‘s stock had its “buy” rating reissued by investment analysts at D. Boral Capital in a research report issued to clients and investors on Thursday,Benzinga reports. They presently have a $9.00 price target on the stock.

Several other research firms have also recently weighed in on IVVD. EF Hutton Acquisition Co. I upgraded Invivyd to a “strong-buy” rating in a research report on Wednesday, October 30th. HC Wainwright dropped their price objective on shares of Invivyd from $15.00 to $10.00 and set a “buy” rating for the company in a research note on Wednesday, November 20th. Finally, Morgan Stanley dropped their price objective on Invivyd from $9.50 to $3.55 and set an “overweight” rating for the company in a report on Wednesday, November 20th. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $7.89.

Invivyd Trading Up 3.2 %

Shares of NASDAQ IVVD opened at $0.72 on Thursday. The firm has a market cap of $86.57 million, a P/E ratio of -0.36 and a beta of 0.65. The business’s 50 day moving average is $0.97 and its 200-day moving average is $1.22. Invivyd has a 1-year low of $0.69 and a 1-year high of $5.20.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Barclays PLC increased its position in Invivyd by 179.6% during the 3rd quarter. Barclays PLC now owns 117,973 shares of the company’s stock worth $120,000 after purchasing an additional 75,780 shares in the last quarter. State Street Corp grew its stake in shares of Invivyd by 3.7% during the third quarter. State Street Corp now owns 1,018,640 shares of the company’s stock worth $1,039,000 after buying an additional 35,904 shares during the last quarter. Proficio Capital Partners LLC acquired a new position in shares of Invivyd during the third quarter worth $27,000. Cubist Systematic Strategies LLC lifted its stake in shares of Invivyd by 66.1% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 134,452 shares of the company’s stock valued at $148,000 after acquiring an additional 53,499 shares during the last quarter. Finally, Susquehanna Fundamental Investments LLC acquired a new stake in shares of Invivyd during the 2nd quarter valued at $115,000. Institutional investors and hedge funds own 70.36% of the company’s stock.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.